This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast And Market Analysis Event-Driven Update

Table 2: Treatment Guidelines for Rheumatoid Arthritis 21

Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market 23

Table 4: Treatment Guidelines for Rheumatoid Arthritis 27

Table 5: Product Profile - Enbrel 28

Table 6: 10 year Open-label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 years for Completers 29

Table 7: 10 year Open-label Safety and Efficacy Trial of Enbrel: Safety Results Overall 30

Table 8: Enbrel SWOT Analysis, 2012 32

Table 9: Product Profile - Humira 33

Table 10: Humira SWOT Analysis, 2012 35

Table 11: Product Profile - Remicade 37

Table 12: Remicade SWOT Analysis, 2012 39

Table 13: Product Profile - Simponi 41

Table 14: Simponi SWOT Analysis, 2012 43

Table 15: Product Profile - Cimzia 45

Table 16: Cimzia SWOT Analysis, 2012 47

Table 17: Product Profile - Orencia 48

Table 18: Orencia SWOT Analysis, 2012 50

Table 19: Product Profile - Actemra/RoActemra 52

Table 20: Actemra/RoActemra SWOT Analysis, 2012 54

Table 21: Product Profile - Rituxan 56

Table 22: Rituxan SWOT Analysis, 2012 58

Table 23: Product Profile - Methotrexate 60

Table 24: Methotrexate SWOT Analysis, 2012 61

Table 25: Summary of Minor Therapeutic Classes, 2012 62

Table 26: Overall Unmet Needs - Current Level of Attainment 63

Table 27: Clinical Unmet Needs - Gap Analysis, 2012 66

Table 28: Rheumatoid Arthritis - Phase Pipeline, 2012 68

Table 29: Comparison of Therapeutic Classes in Development for RA, 2012 69

Table 30: Product Profile - Tofacitinib 70

Table 31: Clinical Trial Locations by Country for Tofacitinib 71

Table 32: ORAL Standard ACR 20 Responses for Tofacitinib vs. Placebo vs. Humira at Month 6 71

Table 33: ORAL Step ACR 20, 50, 70 Responses for Tofacitinib vs. Placebo at Month Six 72

Table 34: Efficacy Issues Regarding Tofacitinib Determined by FDA Advisory Panel, May 2012 72

Table 35: Safety Issues Regarding Tofacitinib Determined by FDA Advisory Panel, May 2012 73

Table 36: Tofacitinib Clinical Trial Mortalities as of September 29, 2011 74

Table 37: Tofacitinib SWOT Analysis, 2012 75

2 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs